


BRIEF COMMUNICATION

Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification

Crystal M. Proud¹, Eugenio Mercuri², Richard S. Finkel³, Janbernd Kirschner⁴, Darryl C. De Vivo⁵, Francesco Muntoni^{6,7}, Kayoko Saito⁸, Eduardo F. Tizzano⁹, Isabelle Desguerre¹⁰, Susana Quijano-Roy¹¹, Kamal Benguerba¹², Dheeraj Raju¹³, Eric Faulkner^{13,14,15} & Laurent Servais^{16,17} 

¹Children's Hospital of The King's Daughters, Norfolk, Virginia, USA

²Department of Paediatric Neurology and Nemo Clinical Centre, Catholic University, Rome, Italy

³Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

⁴Department of Neuropediatrics and Muscle Disorders, Medical Center University of Freiburg, Faculty of Medicine, Freiburg, Germany

⁵Departments of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, New York, USA

⁶The Dubowitz Neuromuscular Centre, University College London, Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK

⁷National Institute of Health Research, Great Ormond Street Hospital Biomedical Research Centre, London, UK

⁸Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan

⁹Department of Clinical and Molecular Genetics, Hospital Vall d'Hebron, Barcelona, Spain

¹⁰Hôpital Necker Enfants Malades, APHP, Paris, France

¹¹Garches Neuromuscular Reference Center (GNMH), APHP Raymond Poincaré University Hospital (UVSQ Paris Saclay), Garches, France

¹²Novartis Gene Therapies Switzerland GmbH, Rotkreuz, Switzerland

¹³Novartis Gene Therapies, Inc, Bannockburn, Illinois, USA

¹⁴Institute for Precision and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

¹⁵Genomics, Biotech and Emerging Medical Technology Institute, National Association of Managed Care Physicians, Richmond, Virginia, USA

¹⁶Department of Paediatrics, MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK

¹⁷Department of Paediatrics, Neuromuscular Reference Center, University and University Hospital of Liège, Liège, Belgium

Correspondence

Crystal M. Proud, Children's Hospital of The King's Daughters, 601 Children's Lane, Norfolk, VA 23507, USA. Tel: 1-757-668-9979; Fax: 1-757-668-9930; E-mail: crystal.proud@chkd.org

Received: 26 April 2023; Revised: 17 July 2023; Accepted: 18 July 2023

doi: 10.1002/acn3.51889

Abstract

We sought to devise a rational, systematic approach for defining/grouping *survival motor neuron*-targeted disease-modifying treatment (DMT) scenarios. The proposed classification is primarily based on a two-part differentiation: initial DMT, and persistence/discontinuation of subsequent DMT(s). Treatment categories were identified: monotherapy add-on, transient add-on, combination with onasemnogene abeparvovec, bridging to onasemnogene abeparvovec, and switching to onasemnogene abeparvovec. We validated this approach by applying the classification to the 443 patients currently in the RESTORE registry and explored the demographics of these different groups of patients. This work forms the basis to explore the safety and efficacy profile of the different combinations of DMT in SMA.

Introduction

Survival motor neuron (SMN)-targeted, disease-modifying treatments (DMTs) have demonstrated efficacy and safety as single therapies across many clinical trials and are now well established as standard of care for patients with spinal muscular atrophy (SMA).^{1–5} Despite a lack of clinical trial and real-world data to demonstrate the clinical benefit (or risk) associated with the administration of more

than one SMN-targeted DMT in combination or in sequence, a clear trend exists for the use of more than one DMT in specific circumstances (e.g., initiating bridge treatment with nusinersen or risdiplam while awaiting decline of anti-AAV9 [adeno-associated virus serotype 9] antibody titers to a concentration that permits onasemnogene abeparvovec administration or physician or caretaker desire to switch treatment in an effort to optimize patient outcomes).^{6–13}

No systematic approach has been proposed to classify the various combination treatment scenarios for patients with SMA who receive DMTs and to facilitate analyses that will clarify potential benefit–risk differences between treatment regimens, including regimens incorporating one-time gene replacement therapy. The relative prevalence of different regimens is also poorly understood. We sought to devise a rational, systematic, broadly applicable approach for defining and grouping *SMN*-targeted DMT treatment scenarios that will facilitate future analyses aimed at exploring potential differences in clinical outcomes and address evidence gaps in the developing field of SMA DMTs. We also sought to describe the relative prevalence of various *SMN*-targeted DMT scenarios observed in the RESTORE registry (NCT04174157), a prospective, multicenter, multinational, noninterventional, treatment-neutral registry of patients with SMA, which was designed to integrate with existing real-world data.¹⁴

Methods

To classify various treatment scenarios, definitions were developed by a group of neuromuscular experts representing a broad geographic range and varied clinical practice settings. Once consensus was reached on treatment definitions, these definitions were applied to patients enrolled in the RESTORE registry¹⁴ (as of 20 December 2022) to examine the relative real-world prevalence of each treatment strategy.

Results

Our proposed treatment classification is primarily based on a two-part differentiation: initial therapy received (gene therapy or *SMN2* splicing modifier) and persistence or discontinuation of subsequent DMT(s). This resulted in six polytherapy treatment categories: add-on, transient add-on, combination with onasemnogene abeparvovec, bridge to onasemnogene abeparvovec, switch to onasemnogene abeparvovec, and nusinersen/risdiplam combinations (Fig. 1). Because onasemnogene abeparvovec is a one-time therapy that provides ongoing *SMN* protein expression, any treatment administered after infusion with onasemnogene abeparvovec is termed add-on. Add-on treatment to onasemnogene abeparvovec that is discontinued is termed transient. Combination treatment includes initial treatment with nusinersen and/or risdiplam with ongoing or added treatment after infusion with onasemnogene abeparvovec. Bridge therapy is short-term treatment with nusinersen or risdiplam serving as a bridge to gene therapy with onasemnogene abeparvovec.¹² Switching therapy is longer term treatment with nusinersen or risdiplam prior to receiving onasemnogene abeparvovec.¹³

Bridging and switching are distinguished based on duration of therapy with an initial *SMN2* splicing modifier before the use of gene therapy, with bridging a short-duration (loading doses only for nusinersen or risdiplam treatment for ≤ 3 months) and switching a longer duration (one or more nusinersen maintenance dose or risdiplam treatment for > 3 months). We defined discontinuation as two or more consecutive missed doses based on the expected dosing schedule (nusinersen) or no doses within the last 30 days (risdiplam). Durations for bridging and switching were adopted as reasonable surrogates for distinguishing these two treatment patterns in the absence of direct knowledge of caregiver/provider intent. Definitions for discontinuation were adopted based on previously published/presented analyses.^{15,16} Importantly, the actual time on nusinersen therapy before discontinuation is variable depending on phase of treatment (loading doses or maintenance doses).

As we described the relative prevalence of the various proposed *SMN*-targeted DMT treatment scenarios, RESTORE data were available for 443 patients at the 20 December 2022, data cutoff (Table 1; see Fig. 1). Of the patients in this analysis who initiated treatment with onasemnogene abeparvovec, 84.0% ($n = 194/231$) received monotherapy compared with 27.4% (58/212) of patients initiating treatment with either nusinersen or risdiplam (nusinersen monotherapy, $n = 49$; risdiplam monotherapy, $n = 9$). Of the 37 patients receiving add-on DMT, treatment was ongoing at the time of data cutoff for 32 out of 37 patients (86.5%), with five patients receiving transient add-on therapy. Of the 150 patients receiving onasemnogene abeparvovec after initial nusinersen or risdiplam, 38.7% ($n = 58/150$) received short-term bridging therapy, 44.7% (67/150) received switching therapy, and 16.7% ($n = 25/150$) received combination with onasemnogene abeparvovec. Nusinersen/risdiplam combination therapy was uncommon in this patient sample, accounting for $< 1\%$ of patients ($n = 4$).

We also assessed patient demographics and characteristics associated with monotherapy and the proposed add-on and combination *SMN*-targeted DMT treatment scenarios (add-on, transient add-on, combination with onasemnogene abeparvovec, bridge to onasemnogene abeparvovec, and switch to onasemnogene abeparvovec) for patients from RESTORE who had received one-time gene replacement therapy with onasemnogene abeparvovec (Table S1). The greatest percentage of patients in each treatment group had two *SMN2* copies (range: 44.4%–100%) and SMA type 1 (range: 33.3%–100%), except for patients receiving nusinersen monotherapy, with the greatest percentage of patients having three *SMN2* copies (61.2%) and SMA type 3 (47.0%). Overall, patient demographics and clinical characteristics were similar between

Proposed Treatment Term	Proposed Definition
Monotherapy	Patient only treated with one DMT and who has not received any dose of another DMT (i.e., onasemnogene abeparvovec monotherapy, nusinersen monotherapy, risdiplam monotherapy)
Add-on	Patient treated with onasemnogene abeparvovec and, subsequently, with any other SMN-targeting DMT (because once administered, gene therapy cannot be stopped and always contributes to patient outcomes) <i>and treatment with other DMT is ongoing</i>
Transient Add-on (a subset of add-on)	Patient treated with onasemnogene abeparvovec and, subsequently, with any other SMN-targeting DMT (because once administered, gene therapy cannot be stopped and always contributes to patient outcomes) <i>and treatment with other DMT has been discontinued</i>
Combination with onasemnogene abeparvovec	Patient initially treated with nusinersen and/or risdiplam with ongoing (or added) treatment post-onasemnogene abeparvovec infusion
Bridge to onasemnogene abeparvovec	Patient infused with onasemnogene abeparvovec after treatment initiated with nusinersen or risdiplam Patient treated with short-duration nusinersen or risdiplam: Loading doses only for nusinersen or risdiplam treatment for ≤3 months
Switch to onasemnogene abeparvovec	Patient infused with onasemnogene abeparvovec after treatment initiated with nusinersen or risdiplam Patient treated with longer duration nusinersen or risdiplam: ≥1 nusinersen maintenance dose or risdiplam treatment for >3 months
Nusinersen/risdiplam Combinations	Patient has been treated with both nusinersen and risdiplam, in any sequence and regardless of discontinuation, but has not been treated with onasemnogene abeparvovec
Discontinuation of nusinersen/risdiplam	Nusinersen and risdiplam discontinuation criteria: <ul style="list-style-type: none"> Nusinersen: ≥2 consecutive missed doses based on the expected dosing schedule per product label Risdiplam: indicated discontinuation (e.g., per study case report form) or no doses within the last 30 days

Potential paths for patient identification and treatment, as of December 20, 2022, data cutoff




Figure 1. Proposed treatment terms and definitions and potential paths for patient identification and treatment. DMT, disease-modifying treatment; N, nusinersen; OA, onasemnogene abeparvovec; R, risdiplam; SMA, spinal muscular atrophy. *SMN, survival motor neuron.* ^aNusinersen/risdiplam discontinued, **or** no doses of nusinersen/risdiplam received after onasemnogene abeparvovec infusion.

Table 1. RESTORE treatment distribution.

Treatment	Patients, n (%)
All RESTORE patients, 20 December 2022, data cutoff	443 (100)
Monotherapy	
Onasemnogene abeparvovec monotherapy	194 (43.8)
Nusinersen monotherapy	49 (11.1)
Risdiplam monotherapy	9 (2.0)
Add-on	32 (7.2)
Transient Add-on	5 (1.1)
Combination with onasemnogene abeparvovec	25 (5.6)
Bridge to onasemnogene abeparvovec	58 (13.1)
Switch to onasemnogene abeparvovec	67 (15.1)
Nusinersen/risdiplam combinations	4 (0.9)

groups for the patients receiving add-on, transient add-on, combinations with onasemnogene abeparvovec, bridging to onasemnogene abeparvovec, and switching to onasemnogene abeparvovec, but varied between the 187 patients in the treatment groups and the 194 patients receiving onasemnogene abeparvovec monotherapy. Approximately half of the patients receiving onasemnogene abeparvovec monotherapy (52.1%) were symptomatic at SMA diagnosis compared with a greater majority of patients in the add-on and combination treatment groups (range: 75.9%–100%). Only 29.9% of patients in the groups receiving add-on or combination *SMN*-targeted DMT treatment scenarios (i.e., add-on, transient add-on, combinations with onasemnogene abeparvovec, bridging to onasemnogene abeparvovec, switching to onasemnogene abeparvovec) were identified by newborn screening (range: 22.4%–46.9%), with the greatest percentage of patients identified by newborn screening receiving onasemnogene abeparvovec monotherapy (58.3%). Despite having similar median age at symptom onset and first treatment, patients in groups receiving add-on, transient add-on, combinations with onasemnogene abeparvovec, bridging to onasemnogene abeparvovec, and switching to onasemnogene abeparvovec treatment scenarios were older at SMA diagnosis (median age 3 months) compared with patients receiving onasemnogene abeparvovec monotherapy (median age 1 month). The 187 patients in the groups receiving add-on, transient add-on, combinations with onasemnogene abeparvovec, bridging to onasemnogene abeparvovec, and switching to onasemnogene abeparvovec treatment scenarios were heavier (median weight 7.5 kg) and older (median age 9 months) compared with the 181 patients receiving onasemnogene abeparvovec monotherapy with weight data available (median weight 5.2 kg, median age 3 months). Most patients had a 1-month interval between diagnosis and treatment, except for patients receiving nusinersen

monotherapy (median interval, 2 months) and bridging to onasemnogene abeparvovec (median interval, 0 months).

Discussion

Our description of the relative prevalence of the various *SMN*-targeted DMT treatment scenarios observed in the RESTORE registry has some limitations. Although a global disease registry, RESTORE has primarily enrolled patients treated in the United States, and treatment patterns in other parts of the world may differ. In addition, treatment regimens that include only the two *SMN2* splicing modifiers (nusinersen and risdiplam) may be under-represented, and our proposed classification does not differentiate between various potential combination scenarios involving only the two *SMN2* splicing modifiers (nusinersen and risdiplam). However, our classification system reflects the authors' collective expert opinion that the primary interest in differentiating treatment sequences or combinations for SMA lies with regimens that include onasemnogene abeparvovec because, unlike nusinersen or risdiplam, the gene therapy will theoretically continue to produce sufficient functional *SMN* protein over the lifetime of the patient.

Several potential treatment scenarios are encompassed within the "Combination with onasemnogene abeparvovec" group. Although it is possible that these various scenarios could be associated with important differences in clinical outcomes, multiple variables (e.g., age at diagnosis, duration of symptoms, timing of treatments, disease severity at treatment initiation) confound answering this question. Small patient numbers representing each specific (often unique) scenario preclude meaningful analysis of outcomes within this group. All treatment groups include infants identified at risk for SMA by newborn screening as well as clinically diagnosed patients, indicating a potentially significant degree of heterogeneity within each group that may complicate analysis of differential outcomes by treatment regimen. Alternative means of classifying and differentiating SMA combination treatment groups are possible. We believe, however, that our proposed system is broadly applicable and does not preclude stratification according to other criteria (e.g., according to patient age during combination therapy, or analyses that consider ongoing exposure to previously administered *SMN2* splicing modifiers [i.e., analyses that consider the half-life of these treatments]) that may be more suitable to approach specific clinical questions. Our classification exercise was limited to *SMN*-targeting treatments for SMA. Although clinical trials investigating new classes of SMA treatments (e.g., apitegromab, a selective myostatin inhibitor) are currently underway,¹⁷ present experience

with these new treatments in real-world practice is insufficient to inform rationale for integration into a classification schema such as this. Clinical experience with investigational myostatin inhibitors has thus far been limited to older patients with SMA (≥ 2 years of age), and the majority of the incident SMA population now receiving initial (and potentially additional) treatment are well below this age. Our classification schema could be expanded in the future to include non-SMN-directed treatments, as well as other treatments currently under investigation for older SMA patients, such as intrathecal onasemnogene abeparovect.

Although add-on treatment was ongoing as of the data cutoff in the majority of cases, this percentage is certain to fluctuate over time. We expect that patient “migration” between treatment groups will be common as treatments are initiated and discontinued. In this cohort from RESTORE, the majority of patients who initiated treatment with either nusinersen or risdiplam continued on to receive onasemnogene abeparovect. Future analyses will explore the rationales for add-on and combination treatments, and alignment of stated rationale with patient status at the time of add-on initiation. We will also explore clinical outcomes (including motor function assessments, motor milestone achievements, adverse events, and duration of additional treatment) for patients in the RESTORE registry according to these treatment definitions.

Author Contributions

All authors contributed to the conception and design of this study. All authors contributed to analysis discussions, acquisition and analysis of data, and all authors reviewed and edited the manuscript, and approved its submission.

Acknowledgments

This analysis was funded by Novartis Gene Therapies, Inc. Medical writing and editorial support was provided by Wynne Dillon, MS, of Kay Square Scientific, Newtown Square, PA, USA, and David Wolff, MS, of Novartis, Cambridge, MA, USA. This support was funded by Novartis Gene Therapies, Inc. Nicole Guset of SMA Schweiz, Heimberg, Switzerland, and SMA Europe, Frieberg, Germany, was a member of the RESTORE steering committee and was part of the discussions that contributed to this analysis. The authors wish to thank the RESTORE investigators and site coordinators and, most importantly, all the patients, families, and caregivers for their willingness to participate in this registry, which is sponsored by Novartis Gene Therapies, Inc.

Conflict of Interest

CMP is a site principal investigator for Astellas, Biogen, Catabasis, CSL Behring, Novartis Gene Therapies, Inc., Pfizer, PTC, Sarepta, and Scholar Rock clinical trials, and has received honoraria for advisory board participation from Biogen, Novartis Gene Therapies, Inc., Novartis, Roche, and Sarepta; and speaker's fees from Biogen and Novartis Gene Therapies, Inc. **EM** has received personal compensation for clinical trial consulting, serving on scientific advisory boards, and research funding from Novartis Gene Therapies, Inc. **RSF** has received personal compensation for consulting and for advisory board participation from Novartis Gene Therapies, Inc., Biogen, Novartis, Roche, and Scholar Rock; editorial fees from Elsevier for co-editing a neurology textbook; license fees from the Children's Hospital of Philadelphia; and research funding from Novartis Gene Therapies, Inc., Biogen, Roche/Genentech, and Scholar Rock. **JK** has received honoraria for clinical research and/or consultancy activities from Biogen, Novartis Gene Therapies, Inc., Pfizer, Roche, Sarepta and Scholar Rock. **DCD** has received personal compensation for consulting for advisory board participation from Novartis Gene Therapies, Inc., Biogen, Cytokinetics, Ionis Pharmaceuticals, Inc., Mallinckrodt, Metafora, PTC Therapeutics, Roche, Sanofi, Sarepta Therapeutics, and Ultragenyx, and the n-lorem Foundation and SMA Foundation. He has no financial interests in these companies. He has received compensation as a consultant from Novartis Gene Therapies, Inc., Biogen, and Sarepta Therapeutics. He has received research grants from the Hope for Children Research Foundation, National Institutes of Health, SMA Foundation, Cure SMA, GliaPharm, Rocket Pharma, Glut1 Deficiency Foundation, and the US Department of Defense; he also has received clinical trial funding from Biogen, Mallinckrodt, PTC Therapeutics, Sarepta Therapeutics, Scholar Rock, and Ultragenyx; and serves as a member of the DSMB for Aspa Therapeutics. **FM** has received honoraria for scientific advisory board participation from Novartis Gene Therapies, Inc., Biogen, Novartis, Lilly, PTC, Roche, Dyne Therapeutics and Sarepta, and grants and personal fees from Novartis Gene Therapies, Inc., Biogen, and Roche. **KS** is a site principal investigator for Biogen, Novartis Gene Therapies, Inc., and Chugai/Roche clinical trials; has served on advisory boards for Novartis Gene Therapies, Inc./Novartis, Biogen, and Chugai/Roche; and has received speaker's fees from Biogen, Novartis, and Chugai/Roche. **EFT** has received personal compensation for consultancy from Novartis Gene Therapies, Inc., Biogen, Biologiz, Cytokinetics, Novartis, and Roche, and research funding from Biogen/Ionis and Roche. **ID** has received personal compensation for lectures and/or scientific board

meetings from Novartis Gene Therapies, Inc., Biogen, BioMarin, PTC Therapeutics, and Sarepta. **SQ-R** is a site principal investigator for clinical trials of Biogen and Novartis Gene Therapies, Inc.; has served as a consultant and has participated on advisory boards for Novartis Gene Therapies, Inc., Biogen, and Roche; and has received travel and speaker honoraria from Biogen, Novartis, and Roche. **KB**, **DR**, and **EF** are employees of Novartis Gene Therapies and own stock/other equities. **LS** has received personal compensation from Novartis Gene Therapies, Inc., Biogen, Inc., Biophytis, Cytokinetics, Dynacure, Roche, Santhera, and Sarepta Therapeutics, and research funding from Novartis Gene Therapies, Inc., Biogen, Dynacure, and Roche.

References

1. Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscul Disord.* 2018;28(3):197-207.
2. Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. *Nat Rev Dis Primers.* 2022;8(1):52.
3. Spinraza (nusinersen) [package insert]. Biogen, Inc.; 2020.
4. Evrysdi (risdiplam) [package insert]. Genentech, Inc.; 2022.
5. Zolgensma (onasemnogene abeparvovec-xioi) [package insert]. Novartis Gene Therapies, Inc.; 2023.
6. D'Silva AM, Holland S, Kariyawasam D, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. *Ann Clin Transl Neurol.* 2022;9(3):339-350.
7. Ramos-Platt L, Elman L, Shieh PB. Experience and perspectives in the US on the evolving treatment landscape in spinal muscular atrophy. *Int J Gen Med.* 2022;15:7341-7353.
8. Lee BH, Collins E, Lewis L, et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1. *Neurology.* 2019;93:640-641.
9. Harada Y, Rao VK, Arya K, et al. Combination molecular therapies for type 1 spinal muscular atrophy. *Muscle Nerve.* 2020;62:550-554.
10. Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. *Eur J Paediatr Neurol.* 2022;39:1-10.
11. Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. *Eur J Paediatr Neurol.* 2020;28:38-43.
12. Ferrante L, Melendez-Zaidi A, Lindsey W, Lotze T. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy. *Muscle Nerve.* 2022;66:E8-E10.
13. Tosi M, Catteruccia M, Cherchi C, Mizzi I, D'Amico A. Switching therapies: safety profile of onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with risdiplam. *Acta Myol.* 2022;41:117-120.
14. Finkel RS, Day JW, De Vivo DC, et al. RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy – rationale and study design. *J Neuromuscul Dis.* 2020;7:145-152.
15. Fox D, To TM, Seetasith A, Patel AM. Adherence and persistence to nusinersen for spinal muscular atrophy: a US claims-based analysis. *Adv Ther.* 2023;40:903-919.
16. Iannaccone ST, To TM, Dickendesh T, et al. A retrospective analysis of adherence and persistence among risdiplam-treated patients with spinal muscular atrophy (SMA). Poster presented at: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; March 19–22 2023 Dallas, TX, USA.
17. Abati E, Manini A, Comi GP, Corti S. Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases. *Cell Mol Life Sci.* 2022;79(7):374.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1.